- Home
- MCRB vs CABA Comparison
MCRB vs CABA Comparison
Compare MCRB & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- CABA
- Stock Information
- Founded
- MCRB 2010
- CABA 2017
- Country
- MCRB United States
- CABA United States
- Employees
- MCRB N/A
- CABA N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCRB Health Care
- CABA Health Care
- Exchange
- MCRB Nasdaq
- CABA Nasdaq
- Market Cap
- MCRB 165.3M
- CABA 132.6M
- IPO Year
- MCRB 2015
- CABA 2019
- Fundamental
- Price
- MCRB $15.91
- CABA $1.84
- Analyst Decision
- MCRB Hold
- CABA Strong Buy
- Analyst Count
- MCRB 4
- CABA 8
- Target Price
- MCRB $73.67
- CABA $12.75
- AVG Volume (30 Days)
- MCRB 245.4K
- CABA 1.3M
- Earning Date
- MCRB 11-12-2025
- CABA 11-13-2025
- Dividend Yield
- MCRB N/A
- CABA N/A
- EPS Growth
- MCRB N/A
- CABA N/A
- EPS
- MCRB 10.22
- CABA N/A
- Revenue
- MCRB N/A
- CABA N/A
- Revenue This Year
- MCRB N/A
- CABA N/A
- Revenue Next Year
- MCRB N/A
- CABA N/A
- P/E Ratio
- MCRB $1.62
- CABA N/A
- Revenue Growth
- MCRB N/A
- CABA N/A
- 52 Week Low
- MCRB $6.53
- CABA $0.99
- 52 Week High
- MCRB $24.67
- CABA $5.46
- Technical
- Relative Strength Index (RSI)
- MCRB 44.26
- CABA 63.83
- Support Level
- MCRB $17.00
- CABA $1.63
- Resistance Level
- MCRB $24.67
- CABA $1.74
- Average True Range (ATR)
- MCRB 2.01
- CABA 0.10
- MACD
- MCRB -0.50
- CABA 0.03
- Stochastic Oscillator
- MCRB 15.94
- CABA 93.62
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.